Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Buy” by Analysts

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $20.20.

Several equities analysts recently weighed in on ALT shares. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Finally, Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd.

Insider Transactions at Altimmune

In related news, CFO Gregory L. Weaver bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Several hedge funds have recently modified their holdings of the stock. Barclays PLC raised its holdings in shares of Altimmune by 1.1% during the 4th quarter. Barclays PLC now owns 157,528 shares of the company’s stock valued at $1,135,000 after buying an additional 1,787 shares during the period. Rafferty Asset Management LLC grew its stake in Altimmune by 1.3% during the 4th quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company’s stock valued at $1,137,000 after purchasing an additional 1,964 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Altimmune by 2.0% during the 4th quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company’s stock valued at $742,000 after purchasing an additional 2,028 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Altimmune by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company’s stock valued at $945,000 after purchasing an additional 2,162 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Stock Up 13.3%

ALT opened at $6.74 on Friday. The firm has a market cap of $546.66 million, a P/E ratio of -4.35 and a beta of 0.58. Altimmune has a 52 week low of $3.55 and a 52 week high of $11.16. The business’s fifty day simple moving average is $5.17 and its 200 day simple moving average is $6.31.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. During the same period in the prior year, the business posted ($0.34) earnings per share. As a group, equities analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.